Merck said on Monday it would split its business into two, creating a division for its cancer franchise while grouping its non-oncology treatments separately.
After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...
Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.
Tempus AI and Merck announced an expanded multi year collaboration focused on AI driven precision medicine and drug discovery ...
Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple ...
Tempus AI Inc. on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. aimed at accelerating AI-driven ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...
A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...
Zacks Investment Research on MSN
Merck (MRK) rises higher than market: Key facts
In the latest close session, Merck (MRK) was up +1.14% at $117.11. The stock's performance was ahead of the S&P 500's daily ...
Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities. | In a Worker Adjustment and Retraining Notification Act alert filed this ...
The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results